Literature DB >> 31531702

[Rheumatism and bone metabolism].

G Dischereit1,2, U Lange3.   

Abstract

Inflammatory rheumatic diseases are often associated with secondary osteoporosis, as many inflammatory messengers can interfere with bone metabolism and adversely affect it. In addition to a decrease in densitometric bone density, remodeling occurs in the trabecular bone, which can lead to a disturbed microarchitecture and increase the risk of fracture.Central to this is the close integration of bone metabolism and the immune system. Proinflammatory cytokines play an important role not only in the inflammatory process, but also as mediators of bone resorption because they stimulate osteoclastogenesis and induce further signal transduction cascades with negative influence on the bone. The understanding gained in recent years of the underlying immunological processes has led to the development of new and targeted treatment approaches.

Entities:  

Keywords:  Cytokines; Inflammation; Osteoclasts; Osteogenesis; Osteoporosis

Mesh:

Substances:

Year:  2019        PMID: 31531702     DOI: 10.1007/s00132-019-03809-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  24 in total

1.  Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Authors:  Gabriel Dischereit; Ingo H Tarner; Ulf Müller-Ladner; Uwe Lange
Journal:  Clin Rheumatol       Date:  2012-11-24       Impact factor: 2.980

Review 2.  Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.

Authors:  Ellen M Gravallese; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2018-11       Impact factor: 20.543

3.  The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis.

Authors:  Kensuke Kume; Kanzo Amano; Susumu Yamada; Toshikatsu Kanazawa; Hiroyuki Ohta; Kazuhiko Hatta; Kuniki Amano; Noriko Kuwaba
Journal:  Rheumatology (Oxford)       Date:  2014-01-17       Impact factor: 7.580

Review 4.  Denosumab for bone diseases: translating bone biology into targeted therapy.

Authors:  Elena Tsourdi; Tilman D Rachner; Martina Rauner; Christine Hamann; Lorenz C Hofbauer
Journal:  Eur J Endocrinol       Date:  2011-08-18       Impact factor: 6.664

5.  Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register.

Authors:  G Haugeberg; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Arthritis Rheum       Date:  2000-03

6.  High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study.

Authors:  Georg Schett; Stefan Kiechl; Siegfried Weger; Angelo Pederiva; Agnes Mayr; Manuele Petrangeli; Friedrich Oberhollenzer; Rolando Lorenzini; Kurt Redlich; Roland Axmann; Jochen Zwerina; Johann Willeit
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

Review 7.  The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review.

Authors:  Dalit Ashany; Emily M Stein; Rie Goto; Susan M Goodman
Journal:  Curr Rheumatol Rep       Date:  2019-03-12       Impact factor: 4.592

Review 8.  Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling.

Authors:  Cheng-gui Miao; Ying-ying Yang; Xu He; Xiao-feng Li; Cheng Huang; Yan Huang; Lei Zhang; Xiong-Wen Lv; Yong Jin; Jun Li
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

Review 9.  Inflammatory rheumatic disorders and bone.

Authors:  Irene E M Bultink; Marijn Vis; Irene E van der Horst-Bruinsma; Willem F Lems
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

10.  Glucocorticoids: bad or safe for the bones?

Authors:  Willem F Lems
Journal:  RMD Open       Date:  2015-08-15
View more
  1 in total

1.  [Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases : Correlation with conventional bone mineral density measurement and prevalence of vertebral fractures].

Authors:  B Buehring; J Thomas; T Wittkämper; X Baraliakos; J Braun
Journal:  Z Rheumatol       Date:  2020-12       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.